Enbiome Therapeutics aims to harness the power of our microbiome. We identify therapeutic power of individual human microbe. We believe that a microbe is a magic-bullet drug with their millions of years of evolutionary adaptation and polypharmacological capabilities through its various metabolites. We think that the microbiome is an organ and it is possible that providing a “single” missing defined microbial species or a “minimal” combinatorial defined microbial species might be enough to shift the equilibrium of the ecosystem to a net positive therapeutic outcome. We have screened and validated over 1500 bacteria, including many anaerobes, by using our proprietary assay platform. This allows us to screen for more than 107 gene activities. We plan to incrementally expand this screening repertoire to more than 10,000 bacteria, concurrently resulting in a powerful and expansive human microbiome metagenomic library.
Our robust and rapid screening platform for our library of bacteria is carried out in several disease models of Caenorhabditis elegans. We have nearly 50 different C. elegans models most of which express human genes and mutations or their homologs.
C. elegans is also a truer representation of a germ-free model and screening can be carried out in a near natural condition.
Enbiome’s current focus is on 3 disease segments.
NEUROBIOTXTM: Mitochondrial dsyfuction is a nodal point of many neurodegenerative disorders. Parkinson’s, Amyotrophic Lateral Sclerosis (ALS), Huntington’s, Multiple Sclerosis, ADHD and other neurological disorders have one convergent causative factor- mitochondrial dysfunction. Enbiome has identified 6 candidates which can repair mitochondrial dysfunction and promote its biogenesis. We have further tested our selected lead microbes against the various neurological disease models in multiple orthogonal models for each disease.
SKINBIOTXTM: Eczema, Psoriasis and Atopic Dermatitis are allergic skin conditions, which are considered to stem from hyperactivation of our immune system. Skin microbiome of people suffering from allergic skin conditions is dramatically different from healthy individuals. Enbiome believes that the skin microbiome produces compounds that keep our skin immune response under check. We have identified a normal human skin microbe that could correct the improper activation of immune system. We have demonstrated suppression of hyperimmunity as well as ability of the bacterial metabolite to sequester inflammatory peptides.
GUTBIOTXTM: Inflammatory bowel diseases (including Crohn's disease and Ulcerative colitis) and Irritable bowel syndrome are a group of disorders that affect the human gastrointestinal system. Interactions between microbiome and the intestinal cells are important in these chronic conditions. EnBiome's lead candidate produces compounds that upregulate tight junction proteins, thus keeping our intestinal epithelial cells happy and healthy. We have identified a key ingredient from this human gut commensal microbe that is also anti-inflammatory. We are evaluating the strategy of whole bacteria or combination of key active ingredients as a potential therapeutic product.